Related Experiment Video

Updated: May 27, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Ovarian cancer: Stat3, RhoA and IGF-IR as therapeutic targets

Caroline Gest1, Pezhman Mirshahi, Hong Li

  • 1Laboratoire M.E.R.C.I - EA 3829, Faculté de Médecine et de Pharmacie, Université de Rouen, Rouen, France. caroline.gest@yahoo.fr

Cancer Letters
|November 29, 2011
PubMed

Insights

Researchers compared ovarian cancer cell lines to identify therapeutic targets. Highly aggressive cells showed greater invasion and vasculogenic mimicry. Stat3, IGF-IR, and Rho GTPase inhibitors show promise for improving ovarian cancer therapy.

Area of Science:

  • Oncology
  • Cell Biology
  • Biochemistry

Background:

  • Ovarian cancer therapy requires novel strategies targeting aggressive cell phenotypes.
  • Understanding biological differences between varying aggressiveness levels is crucial for treatment development.

Purpose of the Study:

  • To compare biological characteristics of a moderately aggressive ovarian cancer cell line (OVCAR-3) with highly aggressive ones (SK-OV-3 and HASCJ).
  • To identify potential therapeutic targets for improving ovarian cancer treatment by evaluating agents that reduce cancer cell aggressivity.

Main Methods:

  • Comparative analysis of OVCAR-3, SK-OV-3, and HASCJ ovarian cancer cell populations.
  • Assessment of angiogenic factor secretion, Matrigel invasion, and vasculogenic mimicry.
  • Screening of 10 agents for their ability to decrease cancer cell aggressivity in aggressive models.

Main Results:

  • Highly aggressive SK-OV-3 and HASCJ cells exhibited significantly greater cell invasion and vasculogenic mimicry compared to OVCAR-3 cells.
  • Angiogenic factor secretion did not differentiate between cell aggressiveness levels.
  • Inhibitors of Signal Transducer and Activator of Transcription 3 (Stat3), Insulin-like Growth Factor 1 Receptor (IGF-IR), and Rho GTPase demonstrated the most promising effects in reducing cancer cell aggressivity.

Conclusions:

  • Cell invasion and vasculogenic mimicry are key discriminators of ovarian cancer cell aggressiveness.
  • Stat3, IGF-IR, and Rho GTPase pathways represent promising therapeutic targets for advanced ovarian cancer.

More Related Videos

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-107:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...